Evofem Biosciences, Inc.

Equities

EVFM

US30048L3024

Pharmaceuticals

Market Closed - OTC Markets 03:58:24 2024-04-23 pm EDT 5-day change 1st Jan Change
0.0128 USD -19.25% Intraday chart for Evofem Biosciences, Inc. -16.34% -80.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Evofem Biosciences, Inc. - Special Call
North American Morning Briefing : Dow Set For New -2- DJ
Laidlaw Downgrades Evofem Biosciences to Hold From Buy MT
Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Evofem Biosciences, Inc. Presents at Virtual Investor Ask the CEO Conference, Oct-24-2023 10:00 AM
Evofem Biosciences, Inc. Provides Sales Guidance for the Third Quarter of 2023 CI
Evofem Biosciences, Inc. announced that it has received $3.504807 million in funding CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher DJ
Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Evofem Biosciences, Inc. announced that it has received $0.65 million in funding CI
Evofem Biosciences, Inc. announced that it has received $1.5 million in funding CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely DJ
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
MEI Pharma's Finance Chief Brian Drazba to Step Down; Company Names Justin File as Successor MT
MEI Pharma Names Justin File as Chief Financial Officer MT
Evofem Biosciences, Inc. Receives Paragraph IV Certification Notice Letter from Padagis Israel Pharmaceuticals Ltd CI
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Evofem Biosciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Evofem Biosciences, Inc. Appoints Ivy Zhang as Secretary CI
Evofem Biosciences, Inc. Announces CFO Changes CI
North American Morning Briefing : Further Caution -2- DJ
Evofem Biosciences, Inc. announced that it has received $0.538461 million in funding CI
Chart Evofem Biosciences, Inc.
More charts
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing advanced products to address unmet needs in women’s sexual and reproductive health. The Company’s first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Additionally, the Company offers women direct access to Phexxi through its telehealth partner. Using this platform, women can have a telehealth visit with a health care provider (HCP) to determine their eligibility for a Phexxi prescription.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0159
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. EVFM Stock
  4. News Evofem Biosciences, Inc.
  5. Evofem Biosciences : Morgan Stanley Downgrades Evofem Biosciences to Underweight Rating From Equal-Weight, Lowers PT to $0.80 From $1